Senate Bill Aims To Restrict Authorized Generics

Law360, New York (February 17, 2011, 2:24 PM EST) -- U.S. Senate Democrats are reviving a proposal to restrict brand-name pharmaceutical companies' ability to market authorized generics during the 180-day exclusivity window following the first successful challenge to a brand patent by a generic-drug maker.

S. 373, the Fair Prescription Drug Competition Act, was introduced in the Senate on Wednesday by Sens. Jay Rockefeller, D-W.Va.; Jeanne Shaheen, D-N.H.; Patrick Leahy, D-Vt.; Daniel Inouye, D-Hawaii; Debbie Stabenow, D-Mich.; and Charles Schumer, D-N.Y.

The legislation, which mirrors a similar bill introduced in several past sessions of Congress, aims...
To view the full article, register now.